SCHEMBL2332894

SCHEMBL2332894

O=C(COc1ccc2ccccc2c1)Nc1cc(C(=O)O)cc(C(=O)O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.66
LMNA P02545 1/20 0.66
STAT3 P40763 1/20 0.66
MEN1 O00255 12/20 0.64
KMT2A Q03164 12/20 0.64
POLB P06746 6/20 0.64
CASP3 P42574 1/20 0.64
SENP8 Q96LD8 1/20 0.64
SENP7 Q9BQF6 1/20 0.64
SENP6 Q9GZR1 1/20 0.64
TDP1 Q9NUW8 2/20 0.61
PPARG P37231 2/20 0.59
NCOA2 Q15596 2/20 0.59
NCOA1 Q15788 2/20 0.59
NCOA3 Q9Y6Q9 2/20 0.59
HTT P42858 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
NR2E3 Q9Y5X4 1/20 0.59
NCOR2 Q9Y618 1/20 0.59
CYP1A2 P05177 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2958454 0.90 HIF1A (0.71) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL4738194 0.87 GALR3 (0.79) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL26482862 0.84 MEN1 (0.54) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL9042503 0.82 GALR3 (0.67) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL9041430 0.80 GALR3 (0.68) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL11888627 0.80 GALR3 (0.68) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL3502253 0.80 KMT2A (0.73) MEN1KMT2APOLBNPSR1NPC1
SCHEMBL7243165 0.79 MAPT (0.60) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL5622828 0.78 MEN1 (1.00) GALR3LMNASTAT3MEN1KMT2A
SCHEMBL30970330 0.77 KMT2A (0.67) GALR3LMNASTAT3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY THE WISTAR INSTITUTE (US) 2016-03-10 US disclosed
US-9234230-B2 Screening method and compounds for modulating telomerase activity THE WISTAR INSTITUTE (US) 2016-01-12 US disclosed
US-8377992-B2 TRBD-binding effectors and methods for using the same to modulate telomerase activity THE WISTAR INSTITUTE (US) 2013-02-19 US disclosed
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity THE WISTAR INSTITUTE (US) 2012-12-06 US disclosed
WO-2011097600-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY THE WISTAR INSTITUTE (US) 2011-08-11 WO disclosed
US-20100160260-A1 TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity THE WISTAR INSTITUTE 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity TERT, TERB1, TERF2 GALR3 3579/4885LMNA 2196/4885STAT3 1858/4885
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY TERT, TERB1, TERF2 GALR3 3579/4885LMNA 2196/4885STAT3 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.